Dr. Tim Greten: Looking forward to Immunotherapy 4.0 era of Hepatocellular Carcinoma
Primary hepatocellular carcinoma is one of the most common malignant tumors in China, ranking second in the mortality rate of malignant tumors in the country. In recent years, significant progress has been made in HCC immunotherapy, bringing new hope to countless HCC patients. The evolution of HCC immunotherapy has gone through the era of PD-1/PD-L1 monotherapy 1.0, combined molecular targeted drug application 2.0, and further combined local treatment 3.0. With ongoing clinical research, the effectiveness of HCC immunotherapy has greatly improved. So, what will the era of HCC immunotherapy 4.0 look like? What challenges will we face next? At the recently concluded 17th International Liver Cancer Association (ILCA) Annual Meeting, Hepatology Digest had the honor of conducting an in-depth interview with Dr. Tim Greten from the National Institutes of Health and the National Cancer Institute's Cancer Research Center.